This study is in progress, not accepting new patients
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Wanxing Chai-Ho, MD

Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Wanxing Chai-Ho, MD
HS Assistant Clinical Professor, Medicine. Authored (or co-authored) 15 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Equillium
- Links
- Company website Sign up for this study
- ID
- NCT05263999
- Phase
- Phase 3 Graft Versus Host Disease Research Study
- Study Type
- Interventional
- Participants
- Expecting 200 study participants
- Last Updated